Raiffeisen Bank International AG Makes New $1.78 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Raiffeisen Bank International AG acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,866 shares of the medical device company's stock, valued at approximately $1,784,000.

Other institutional investors have also recently made changes to their positions in the company. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of DexCom in the 4th quarter valued at about $33,000. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Piper Sandler dropped their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group boosted their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $98.11.

DexCom Stock Up 0.4%

Shares of DXCM traded up $0.38 during trading hours on Tuesday, reaching $87.34. The company's stock had a trading volume of 2,743,312 shares, compared to its average volume of 4,359,184. The firm has a market cap of $34.25 billion, a price-to-earnings ratio of 61.08, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $131.76. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $72.33 and a two-hundred day moving average of $77.80.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.